Language: English Clinical Trial Program HAL Allergy engages in a clinical trial program for global relevant allergens Striving to fill the gap of significantly needed therapeutics for respiratory and food allergies, HAL Allergy engages into a targeted development process clinical studies in human volunteers answer questions on the validity and productivity of the developed therapeutics’ safety and efficiency. Clinical trials are split into several phases with separate research goals in each phase and proceed over many years. Phases of clinical trials Pre-clinical trials are conducted before entering in human trials, including in-vivo testing. Phase I trials assess the safety of a new medicine. This initial phase of testing usually includes a small number of allergic patients focusing on potential side effects of the new treatment at different dose levels. Phase II trials test the safety and efficacy of a new medicine. In this phase the optimal dose of the medicine is determined by testing different dosages. This second phase involves up to several hundred patients in a blinded study. This set-up allows a careful and objective investigation of the safety and effectiveness of the new medicine. Phase III trials are confirmatory trials whereby the safety and efficacy of the new medicine is investigated in larger populations of several hundred to several thousand patients using the selected dose. This large-scale testing yields a more thorough understanding of the effectiveness of the new medicine and its benefit risk ratio. Once Phase III is successfully completed a dossier is submitted to apply for registration and marketing authorization of the new medicine. The future-oriented HAL Allergy clinical trial program HAL Allergy is involved in an ambitious clinical trial program to develop medicines with blockbuster potential for respiratory allergies, such as house dust mite and ragweed, and food allergies, such as peanut and tree nuts. We conduct our clinical trial program under the Therapy Allergen Ordinance (Therapie Allergene Verordnung), the regulatory process under which immunotherapies that were on the German market when the regulation came into effect (Nov 14, 2008) will be licensed. All our clinical trials are registered in an official public database, click here. At HAL Allergy we are committed to the safety of patients who take part in our trials, and we uphold the highest ethical standards in all of our clinical research activities. Our clinical trials are performed by experienced physicians in the field of allergy at highly qualified clinical research sites. Contact Company Information Terms of Use Privacy & Cookie Policy Distributors © Copyright 2020 HAL Allergy B.V., All rights reserved. Design by AJB. HAL Allergy uses cookies to optimize the design of and continuously improve this website. By continuing your visit of the website, you consent to the use of all cookies. If this is not what you want, please go to Settings and more information to find out which cookies we place and make your choice. I accept Privacy settings